Salzburg

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Prostate cancer2 trials
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Head and neck cancer1 trial
• Heart failure1 trial
• Sarcoma1 trial

Phase

• Phase 37 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Active, not recruiting6 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• AstraZeneca7 trials
• Acerta Pharma BV1 trial
• Daiichi Sankyo1 trial

Running trials

• Recruiting

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· Phase 3· AstraZeneca· Source

• Recruiting

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· Phase 2/3· Daiichi Sankyo· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Recruiting

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

  NCT03819465· Phase 1· AstraZeneca· Source

• Active, not recruiting

  Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

  NCT03043872· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Prostate cancer1 recruiting